Average Co-Inventor Count = 3.43
ph-index = 4
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Allergan, Inc. (22 from 2,285 patents)
22 patents:
1. 10881608 - Biodegradable intravitreal tyrosine kinase implants
2. 10493082 - 4-pregenen-11β-17-21-triol-3,20-dione derivatives
3. 10188665 - Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
4. 10188667 - Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives
5. 10076492 - Biodegradable intravitreal tyrosine kinase implants
6. 9820995 - Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
7. 9717743 - Pharmaceutical compositions and methods of use of 4-pregenen-11β-17-21-triol-3,20-dione derivatives
8. 9433631 - 4-pregenen-11β-17-21-triol-3,20-dione derivatives
9. 9259429 - Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues
10. 9233070 - Biodegradable intravitreal tyrosine kinase implants
11. 8969583 - 3-phenyl-5-ureidoisothiazole-4-carboximide and 3-amino-5-phenylisothiazole derivatives as kinase inhibitors
12. 8968766 - Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods
13. 8906892 - 4-pregenen-11β-17-21-triol-3,20-dione derivatives
14. 8865691 - Pharmaceutical compositions and methods of use 4-pregenen-11β-17-21-triol-3,20-dione derivatives
15. 8840872 - Ocular therapy using glucocorticoid derivatives selectively penetrating posterior segment tissues